Dr. Chittoor on Guidelines for Liquid Biopsies in NSCLC

Video

Sreeni Chittoor, MD, FACP, discusses the FDA and National Comprehensive Cancer Network recommendations for use of liquid biopsies in patients with non–small cell lung cancer.

Sreeni Chittoor, MD, FACP, a medical oncologist and hematologist at Texas Oncology, discusses the FDA and National Comprehensive Cancer Network (NCCN) recommendations for use of liquid biopsies in patients with non—small cell lung cancer (NSCLC).

The FDA has approved liquid biopsies for identifying EGFR mutations, such as exon 19 deletion and for use on patients who progress on first-line EGFR TKIs, explains Chittoor. Liquid biopsies are often used to identify the most common EGFR mutation, T790M, which is found in about 50% to 60% of patients with NSCLC, says Chittoor.

However, the NCCN has guidelines recommending broader molecular testing, including use of the LungSEQ and 50SEQ panels. With LungSEQ, there are different molecular markers being looked at, which in addition to EGFR include ROS1, ALK, BRAF, NTRK, RET, MET, AKT1, PTEN, and HER2, concludes Chittoor.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,